Our research group uses high-throughput methods to study both genetics and epigenetics in Mendelian and complex diseases. We are also involved in numerous projects trying to understand the influence of epigenetic variation on more complex phenotypes. For example, the effect of medications taken during pregnancy on a child’s neurodevelopment and DNA methylation. Our NSC group is responsible for running the core Illumina sequencing at AMG.

• The Norwegian Sequencing Centre (NSC; sequencing.uio.no). The national core facility for high-throughput sequencing.
• Exome sequencing in immunodeficiencies, OUS
• PharmaTox: Epigenetic effects of medications during pregnancy, OUS/UiO.(https://www.mn.uio.no/farmasi/english/research/groups/pharmatox/)
• miRNA profiling from the Janus Cancer Biobank, Kreftregisteret/OUS
• Centre for Fertility and Health, FHI. (https://www.fhi.no/en/more/research-centres/Centre-for-fertility-and-health/)

Contact information
Group Leader Robert Lyle
Tel: (+47) 22 11 98 74
Department of Medical Genetics and Norwegian Sequencing Centre (NSC)
Pharmatox Strategic Research Initiative
School of Pharmacy, UiO  
E-mail: Robert.Lyle@medisin.uio.no

Contact information
Group Leader Robert Lyle
Tel: (+47) 22 11 98 74
Department of Medical Genetics and Norwegian Sequencing Centre (NSC)
Pharmatox Strategic Research Initiative
School of Pharmacy, UiO  
E-mail: Robert.Lyle@medisin.uio.no